Israeli medical device developer Magenta Medical recently closed a $55 million financing round. The new funding will be used primarily to help Magenta attain FDA approval for its flagship product — a percutaneous left ventricular assist device called Elevate.
A Roche drug that failed as a treatment for neurological disorders is now the lead program for Disc Medicine. CEO John Quisel said Roche's clinical data showed the small molecule's promise addressing a rare blood disorder and now the biotech startup has $90 million to advance that drug and another one into Phase 2 testing.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Incubated by OribMed and led by Ariad Pharmaceuticals veterans, Theseus Pharmaceuticals unveiled $100 million in Series B financing to develop the next generation of tyrosine kinase inhibitors, a type of cancer drug. The company expects to enter the clinic by the end of 2021.
The company is currently running a Phase I study of its lead candidate, the antibody-drug conjugate VLS-101, in patients with lymphomas and leukemias. It has two additional antibody-drug conjugates and a bispecific antibody in preclinical development.
The company hopes the funding will move it toward the clinic. Active clinical programs of gene therapies in Parkinson's include efforts by Voyager Therapeutics and a university in Japan.
The Suzhou-based firm plans to use the money to advance its therapies, currently in clinical development in China and Australia.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The company is currently running a Phase I study in prostate cancer and plans to advance additional therapies into Phase I trials and IND-enabling studies next year.
The company joins a growing wave of firms developing drugs for the disease, which has no approved treatments. It expects to enter two drugs into the clinic next year.
The new company is headquartered in San Francisco, with R&D in Israel and has launched a Phase I study of BIO89-100, formerly TEV-47948.
The Basel, Switzerland-based biotech company plans to trial the drug in achondroplasia patients next year.
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Interleukin-2 has been plagued by low responses and scary side effects but Synthorx is adding synthetic amino acids and a polymer to the treatment in an effort to make it a more effective cancer therapy
Life science incubators and accelerators are expanding and broadening their value-adds, as highlighted on Thursday by two significant announcements; one from Boston, one from Israel.
So far, investments from OrbiMed Israel Partners II include gene therapy company, logicBio and a digital health company focused on protecting patient data in the context of medical research, called MDClone.
A high profile Super Bowl commercial by pharmaceutical company Valeant and the UK's health system pledged to spend $6.1 billion to go paperless and help shift patients with chronic conditions to remote monitoring.
The company also just acquired Israel-based Applied Immune Technologies, meant to fine tune its development of monoclonal antibodies.